Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CHRU De Nancy
Sponsor

CHRU De Nancy

France Co N°34, 29 Avenue Du Mal De Lattre De Tassigny, Bp 60034, 54035 Nancy, France

About the sponsor

CHRU De Nancy supports clinical research in septic shock, cardiogenic shock, and out-of-hospital cardiac arrest, with attention to acute organ support, hemodynamic stability, and neurological outcome. Its trial portfolio also includes advanced therapy for severe circulatory failure and short-term intensive care management.

  • Septic shock
  • Cardiogenic shock
  • Out-of-hospital cardiac arrest
  • Levosimendan and inotropic support

Research in this area also extends to heart failure outcomes and the management of major acute cardiovascular complications.

About Specializations

CHRU De Nancy runs clinical trials in conditions such as Renal transplant, Cardiogenic shock, Metabolic dysfunction-associated steatohepatitis, Spina bifida, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

17 clinical trials

Metabolic dysfunction-associated steatohepatitis

Recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:CHRU De Nancy

Spina bifida

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:OXYBUTYNIN HYDROCHLORIDE
  • Sponsor:CHRU De Nancy

Septic shock

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Albumin
  • Sponsor:CHRU De Nancy

Cardiogenic shock

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:CHRU De Nancy

Ischaemic stroke

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:CHRU De Nancy

Acute graft versus host disease+1

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Methoxsalen
  • Sponsor:CHRU De Nancy

Study on Everolimus and Lutetium (177Lu) Oxodotreotide for Treating Grades 2 and 3 Refractory Meningioma in Patients

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:CHRU De Nancy

Foetal growth restriction

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Sulfur Hexafluoride
  • Sponsor:CHRU De Nancy

Glioma

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:CHRU De Nancy

Adnexal torsion

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sulfur Hexafluoride
  • Sponsor:CHRU De Nancy

Cardiac arrest

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine Bitartrate
  • Sponsor:CHRU De Nancy

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).